Form 8-K - Current report:
SEC Accession No. 0001628280-20-017370
Filing Date
2020-12-10
Accepted
2020-12-10 17:18:48
Documents
104
Period of Report
2020-12-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20201210_d2.htm   iXBRL 8-K 50046
2 EX-23.1 a12920208-kex231.htm EX-23.1 3000
3 EX-99.1 cpix-20201210.htm   iXBRL EX-99.1 1896348
  Complete submission text file 0001628280-20-017370.txt   10214565

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20201210.xsd EX-101.SCH 78515
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20201210_cal.xml EX-101.CAL 144639
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20201210_def.xml EX-101.DEF 349834
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20201210_lab.xml EX-101.LAB 867420
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20201210_pre.xml EX-101.PRE 593005
9 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20201210_d2_htm.xml XML 1831811
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 201381468
SIC: 2834 Pharmaceutical Preparations